{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"}],"units":"Participants"}],"description":"Progression-free survival will be calculated from the initiation of treatment. Progression is confirmed by biopsy, which will be used as the date of progression.","groups":[{"description":"Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)\n\nIntensity Modulated Radiation Therapy: The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.\n\nchemotherapy: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion","id":"OG000","title":"Radiation Therapy"}],"paramType":"NUMBER","populationDescription":"Percentage of the total patient population with progression-free survival 2 years post treatment","reportingStatus":"POSTED","timeFrame":"2 year","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"percentage of patients"}